NASDAQ:VIR Vir Biotechnology (VIR) Stock Price, News & Analysis $7.38 +0.04 (+0.54%) (As of 05:11 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Vir Biotechnology Stock (NASDAQ:VIR) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Vir Biotechnology alerts:Sign Up Key Stats Today's Range$7.14▼$7.4550-Day Range$6.74▼$10.1752-Week Range$6.56▼$13.09Volume413,977 shsAverage Volume1.08 million shsMarket Capitalization$1.02 billionP/E RatioN/ADividend YieldN/APrice Target$36.40Consensus RatingModerate Buy Company OverviewVir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.Read More… Vir Biotechnology Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks41st Percentile Overall ScoreVIR MarketRank™: Vir Biotechnology scored higher than 41% of companies evaluated by MarketBeat, and ranked 680th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingVir Biotechnology has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 3 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageVir Biotechnology has only been the subject of 3 research reports in the past 90 days.Read more about Vir Biotechnology's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Vir Biotechnology are expected to decrease in the coming year, from ($3.36) to ($3.78) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vir Biotechnology is -1.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vir Biotechnology is -1.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVir Biotechnology has a P/B Ratio of 0.62. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.06% of the float of Vir Biotechnology has been sold short.Short Interest Ratio / Days to CoverVir Biotechnology has a short interest ratio ("days to cover") of 5.2.Change versus previous monthShort interest in Vir Biotechnology has recently increased by 11.80%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVir Biotechnology does not currently pay a dividend.Dividend GrowthVir Biotechnology does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted7.06% of the float of Vir Biotechnology has been sold short.Short Interest Ratio / Days to CoverVir Biotechnology has a short interest ratio ("days to cover") of 5.2.Change versus previous monthShort interest in Vir Biotechnology has recently increased by 11.80%, indicating that investor sentiment is decreasing significantly. News and Social Media1.3 / 5News Sentiment0.42 News SentimentVir Biotechnology has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Vir Biotechnology this week, compared to 5 articles on an average week.Search InterestOnly 5 people have searched for VIR on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Vir Biotechnology to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Vir Biotechnology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $32,952.00 in company stock.Percentage Held by Insiders15.60% of the stock of Vir Biotechnology is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions65.32% of the stock of Vir Biotechnology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Vir Biotechnology's insider trading history. Receive VIR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vir Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Email Address VIR Stock News HeadlinesFDA revokes EUAs for some antibody treatments for COVID-19December 23 at 4:11 PM | markets.businessinsider.comVir Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceDecember 18, 2024 | businesswire.comHow Low-Cost Stocks Generate Monthly IncomeAre you ready to transform your investment strategy and generate a steady monthly income? We’re excited to offer you our exclusive report, "Options Trading Strategy: 2 (Surprisingly) Low-Cost Stocks Primed for Generating Monthly Income," FREE!December 24, 2024 | Darwin (Ad)Cautious Hold Rating on Biomea Fusion Amid Uncertainties in Drug Efficacy and Financial OutlookDecember 18, 2024 | markets.businessinsider.comVir receives FDA, EMA designations for tobevibart and elebsiranDecember 13, 2024 | markets.businessinsider.comVir Biotechnology Could Be An Early Riser In 2025 With Oncology Data In JanuaryDecember 13, 2024 | seekingalpha.comVir gets FDA breakthrough therapy status for two drugsDecember 12, 2024 | msn.comVir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA PRIME Designation for Tobevibart and Elebsiran in Chronic Hepatitis DeltaDecember 12, 2024 | businesswire.comSee More Headlines VIR Stock Analysis - Frequently Asked Questions How have VIR shares performed this year? Vir Biotechnology's stock was trading at $10.06 at the start of the year. Since then, VIR shares have decreased by 26.6% and is now trading at $7.38. View the best growth stocks for 2024 here. How were Vir Biotechnology's earnings last quarter? Vir Biotechnology, Inc. (NASDAQ:VIR) announced its earnings results on Thursday, October, 31st. The company reported ($1.56) earnings per share for the quarter, missing analysts' consensus estimates of ($1.05) by $0.51. The firm's revenue for the quarter was down 9.8% compared to the same quarter last year. When did Vir Biotechnology IPO? Vir Biotechnology (VIR) raised $149 million in an IPO on Friday, October 11th 2019. The company issued 7,100,000 shares at $20.00-$22.00 per share. Goldman Sachs, J.P. Morgan, Cowen and Barclays acted as the underwriters for the IPO. Who are Vir Biotechnology's major shareholders? Vir Biotechnology's top institutional shareholders include State Street Corp (4.08%), Baillie Gifford & Co. (1.74%), Geode Capital Management LLC (1.59%) and Charles Schwab Investment Management Inc. (0.82%). Insiders that own company stock include Endurance (Cayman) Ltd Svf, Vicki L Sato, Phillip Pang, Howard Horn, Johanna Friedl-Naderer, Ann M Hanly, George A Scangos, Steven J Rice, Sung Lee, Verneuil Vanina De, Saira Ramasastry, Janet Napolitano, Charles Elliott Sigal and Herbert Virgin. View institutional ownership trends. How do I buy shares of Vir Biotechnology? Shares of VIR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Vir Biotechnology own? Based on aggregate information from My MarketBeat watchlists, some other companies that Vir Biotechnology investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Meta Platforms (META), Home Depot (HD), Moderna (MRNA) and Visa (V). Company Calendar Last Earnings10/31/2024Today12/24/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:VIR CUSIPN/A CIK1706431 Webwww.vir.bio Phone415-906-4324FaxN/AEmployees587Year FoundedN/APrice Target and Rating Average Stock Price Target$36.40 High Stock Price Target$110.00 Low Stock Price Target$12.00 Potential Upside/Downside+393.2%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($3.92) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-615,060,000.00 Net Margins-678.40% Pretax Margin-685.83% Return on Equity-36.71% Return on Assets-31.00% Debt Debt-to-Equity RatioN/A Current Ratio8.94 Quick Ratio8.94 Sales & Book Value Annual Sales$62.04 million Price / Sales16.38 Cash FlowN/A Price / Cash FlowN/A Book Value$11.82 per share Price / Book0.62Miscellaneous Outstanding Shares137,720,000Free Float116,236,000Market Cap$1.02 billion OptionableOptionable Beta0.49 A Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free Report This page (NASDAQ:VIR) was last updated on 12/24/2024 by MarketBeat.com Staff From Our PartnersURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredSix Stocks That Could Soar on Trump’s First Day BackThe recent election results have clarified a path forward, creating opportunities that weren't as clear just m...InvestorPlace | SponsoredTSLA *BANG* incoming (bullet in the chamber rn)I just pinpointed 5 dirt-cheap stocks that could soar the second the shot goes off. Thanks to Donald Trump’...StocksToTrade | SponsoredThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vir Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vir Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.